Wuxi Apptec (2359.HK): 2026 Investor Day takeaway

Wuxi Apptec (603259 CH/2359 HK, Buy) hosted its 2026 Investor Day, titled, 「Enabling through Excellence」 on 6 November, during which management shared sector and company updates. On its sector outlook, management maintained a positive view against the backdrop of active biotech funding, pharmaceutical company R&D expenditure (doubled during the past ten years), and a rising pharmaceutical R&D out-licensing rate (from 54.5% in 2025 to 64.6% in 2035E, according to Frost & Sullivan), combining to drive a global pharmaceutical CRDMO market CAGR of over 12.8% over 2025-30E and a 14% CAGR over 2030-35E. On the Wuxi Biology segment, management highlighted that the company serves AIDD/AI4S clients and mentioned its capacity expansion plan. On the Wuxi Chemistry segment, the key highlights were its track record, capacity strength and tech know-how; the company is currently serving 14 out of 33 synthetic medicines approved by the US FDA in 2025, manufacturing 4 of the global best-selling synthet